Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia

BACKGROUND: Ph-positive leukemias are caused by the aberrant fusion of the BCR and ABL genes. Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely used to treat chronic myelogenous leukemia. Because Ph-positive acute lymphoblastic leukemia only responds tra...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Kaur, Pavinder, Feldhahn, Niklas, Zhang, Bin, Trageser, Daniel, Müschen, Markus, Pertz, Veerle, Groffen, John, Heisterkamp, Nora
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2007
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2169263/
https://ncbi.nlm.nih.gov/pubmed/17958915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-6-67
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items